Morgan Stanley analyst Maxwell Skor assumed coverage of TScan Therapeutics (TCRX) with an Overweight rating and $10 price target Recent Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback